Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
Abstract
Background Patients treated with antipsychotics experience significant weight gain and accompanying metabolic disorders. We investigated the efficacy of liraglutide 3.0 mg in reducing the weight of antipsychotic-treated obese patients. Method We retrospectively reviewed 16 obese patients with schizophrenia or bipolar disorder who were treated with 3.0 mg of liraglutide each. During the 16 weeks of treatment, changes in body weight and Clinical Global Impression-Severity scale (CGI-S) were analyzed. The participants were divided into responders (lost at least 5% of body weight) and non-responders for analysis. Results Treatment with liraglutide 3.0 mg significantly decreased body weight (estimated marginal mean, 93.2 kg at baseline and 88.9 kg at 16 weeks; p Conclusion Liraglutide 3.0 mg significantly decreased body weight in obese patients treated with antipsychotics without altering the status of psychiatric diseases. A randomized controlled study is required to corroborate the results of this study.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Larsen et al. found statistically significantly higher rates of orthostatic hypotension in the liraglutide group compared to control (8.2% vs 0.0%; p=.04).
“Larsen et al. [57] found statistically significantly higher rates of nausea (62.0%vs 32.0%; p-value = .008)and orthostatic hypotension (8.2% vs 0.0%; p-value = .04)in its intervention group compared to its control group.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [57]
Larsen et al. found statistically significantly higher rates of nausea in the liraglutide group compared to control (62.0% vs 32.0%; p=.008).
“Larsen et al. [57] found statistically significantly higher rates of nausea (62.0%vs 32.0%; p-value = .008)and orthostatic hypotension (8.2% vs 0.0%; p-value = .04)in its intervention group compared to its control group.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [57]
Larsen et al. RCT found statistically significant improvement in prediabetes status after 16 weeks of liraglutide (mean difference 9.2%, 95% CI 2.6 to 32.7, p<.001).
“The RCT by Larsen et al. [57] also found statistically significant improvement in prediabetes status after 16 weeks of liraglutide (mean difference (MD): 9.2%, (95% CI: 2.6 to 32.7), p-value <.001).”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [57]
Where commented on, no significant deterioration in mental illness was reported with liraglutide.
“However, where commented on, no significant deterioration in mental illness was reported [55,57,59].”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [57]
Liraglutide trial data is currently only from RCTs conducted using predominantly White European participants.
“It should also be recognised that liraglutide trial data is currently only from RCTs conducted using predominantly White European participants [56,57]; meaning further research in other demographic groups may be beneficial to ascertain generalisability to these groups.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [57]
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · see citing works
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292 · see citing works
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250 · see citing works
Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144 · see citing works
Siskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13167 · Cited by 98 · see citing works
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93 · see citing works
Ebdrup, B. H., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Knop, F. K., & Glenthøj, B. Y. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13204 · Cited by 35 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lee, K., Abraham, S., & Cleaver, R. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.07.006 · Cited by 53 · see citing works
- Authors
- Lee, S. E., Lee, N. Y., Kim, S. H., Kim, K.-A., & Kim, Y. S.
- Affiliations
- Dongguk University Ilsan Hospital (KR)
- Seoul National University (KR)
- Dongguk University (KR)
- Corresponding author
- Kim, Yong Sik
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 299
- Pages
- 113830
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W3131751839
- Cited by
- 27
- References
- 10
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 8 · 2022: 3 · 2021: 1
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, antipsychotic-induced weight gain, obesity, schizophrenia, bipolar disorder, weight loss, GLP-1 receptor agonists, metabolic side effects of antipsychotics, waist circumference, plasma glucose, nausea
- MeSH terms
- Liraglutide, Body Weight, Humans, Hypoglycemic Agents, Obesity, Retrospective Studies, Antipsychotic Agents, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
